Nkarta will present initial clinical data for its natural killer cell therapy in two disorders, myositis and systemic sclerosis, during the American College of Rheumatology annual in Orlando this week. The biotech is part of a growing group of companies developing therapies that reset the immune system to treat autoimmune disease.
The post Nkarta Autoimmune Disease Cell Therapy’s First Human Data Show Safety, Signs of Efficacy appeared first on MedCity News.
